C
Claire N. Harrison
Researcher at Guy's and St Thomas' NHS Foundation Trust
Publications - 511
Citations - 24605
Claire N. Harrison is an academic researcher from Guy's and St Thomas' NHS Foundation Trust. The author has contributed to research in topics: Ruxolitinib & Myelofibrosis. The author has an hindex of 66, co-authored 424 publications receiving 19843 citations. Previous affiliations of Claire N. Harrison include St Thomas' Hospital & National Health Service.
Papers
More filters
Journal ArticleDOI
A phase Ib, open-label, dose-finding study of ruxolitinib in patients (pts) with primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF) and baseline platelets (PLTs) 50 to <100 x 109/l.
Heinz Gisslinger,Mary Frances McMullin,Nadja Jaekel,Carole B. Miller,Srdan Verstovsek,Claire N. Harrison,Giovanni Barosi,Jean-Jacques Kiladjian,H. K. Al-Ali,Denis Weber,Jing Hu,L. Andres Sirulnik,Alessandro M. Vannucchi +12 more
TL;DR: This phase 1b, open-label, dose-finding study in pts with PMF, PPV-MF, or PET-MF and baseline PLT 50-100 x 109/L will evaluate the safety of ruxolitinib and establish the maximum safe starting dose (MSSD) in thrombocytopenic pts with MF.
Journal ArticleDOI
Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies
Ruben A. Mesa,Stacie Hudgens,Lysbeth Floden,Claire N. Harrison,Jeanne Palmer,Vishal Gupta,Donal P. McLornan,Mary Frances McMullin,J J Kiladjian,Lynda Foltz,Uwe Platzbecker,Maria Laura Fox,Adam J. Mead,David L. Ross,Stephen T. Oh,Andrew C. Perkins,Michael F. Leahy,Samineh Deheshi,Rafe M. J. Donahue,Barbara Klencke,Srdan Verstovsek +20 more
TL;DR: In this paper , the authors evaluated longitudinal change from baseline in TSS over the continuous 24-week period and individual symptom scores to obtain a more comprehensive understanding of symptom benefits experienced by patients with myelofibrosis receiving therapy.
Journal ArticleDOI
Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial
Animesh Pardanani,Ayalew Tefferi,Tamas Masszi,Elena Mishchenko,Mark Drummond,Eric Jourdan,Alessandro M. Vannucchi,Mindaugas Jurgutis,Vincent Ribrag,Alessandro Rambaldi,Liang Piu Koh,Shelonitda Rose,Jun Zhang,Claire N. Harrison +13 more
TL;DR: The randomized, placebo (PBO)-controlled, phase III JAKARTA trial evaluated clinical outcomes with fedratinib in pts with JAK-inhibitor-naïve MF, and efficacy and safety analyses were performed for the intention-to-treat (ITT) population.
Journal ArticleDOI
Do we know more about essential thrombocythemia because of JAK2V617F
TL;DR: The discovery of JAK2V617F has led to the proposal that essential thrombocythemia, polycythemia vera, and primary myelofibrosis be discarded as separate diagnoses, and the rationale for this change is discussed.
Journal ArticleDOI
Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX
Claire N. Harrison,Nicolaas Schaap,Alessandro M. Vannucchi,Jean-Jacques Kiladjian,Eric Jourdan,Richard T. Silver,Harry C. Schouten,Francesco Passamonti,Sonja Zweegman,Moshe Talpaz,Srdan Verstovsek,Shelonitda Rose,Juan Shen,Tymara Berry,Carrie Brownstein,Ruben A. Mesa +15 more
TL;DR: Evaluating FEDR safety and efficacy using intention-to-treat (ITT) analyses for all pts enrolled in JAKARTA2 (ITT Population), and for a subgroup of pts who met more stringent definitions for RUX relapsed, refractory, or intolerant ("Stringent Criteria Cohort") than used in the original analysis.